Intel stock extends gains after report of possible U.S. government stake
SAN FRANCISCO - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a $225 million market cap biotech company whose stock has surged nearly 10% in the past week, will present updated clinical data from its ongoing Phase 1b study of tegoprubart for kidney transplant rejection prevention at the World Transplant Congress taking place August 2-6, 2025, according to a press release statement. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt on its balance sheet.
Dr. John Gill from the University of British Columbia will deliver an oral presentation on Wednesday, August 6, featuring results from approximately 30 kidney transplant recipients. The presentation, titled "Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study," is scheduled for 10:00 a.m. PT. With analyst price targets ranging from $8 to $10, significantly above the current trading price of $3.75, market expectations for the company’s research pipeline appear optimistic. InvestingPro subscribers can access 10+ additional exclusive insights about ELDN’s market position and financial outlook.
The company will also sponsor a symposium on August 3 titled "What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?" featuring faculty from various medical institutions.
Additionally, Dr. Andrew Adams from the University of Minnesota will present new preclinical data on tegoprubart for liver transplant rejection prevention in non-human primates during a poster session on August 3.
Tegoprubart is Eledon’s investigational anti-CD40L antibody designed to target CD40 Ligand, which plays a role in immune cell activation and function. The company is studying the drug candidate in kidney transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS).
Irvine, California-based Eledon Pharmaceuticals develops immune-modulating therapies for life-threatening conditions. The company maintains a healthy liquidity position with a current ratio of 13.91, indicating strong ability to meet short-term obligations. According to InvestingPro data, the company’s overall financial health score is rated as GOOD, despite not yet achieving profitability.
In other recent news, Eledon Pharmaceuticals reported a net loss of $0.08 per basic share for the first quarter of 2025. Following this earnings report, Stifel analysts updated their financial model, improving the operating expense forecast and raising earnings per share estimates for 2025 and 2026. Cantor Fitzgerald maintained its Overweight rating on Eledon Pharmaceuticals, indicating confidence in the company’s development strategy and potential market opportunities. The firm reiterated this rating after a Fireside Chat with Eledon’s leadership team, which highlighted the company’s focus on developing tegoprubart for kidney transplants. Tegoprubart, a CD40L antibody inhibitor, aims to replace calcineurin inhibitors, which are linked to nephrotoxicity and graft failure. H.C. Wainwright also expressed optimism by assuming coverage with a buy rating and a $9.00 price target, noting tegoprubart’s potential improved efficacy. Interim results from Eledon’s Phase 1b trial showed that tegoprubart is generally safe and well-tolerated in kidney transplant patients. The company’s ongoing clinical trials and strategic goals continue to attract attention from analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.